Search Result

Results for "

monoamine oxidase B (MAO-B)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Monoamine Oxidase (50) Adenosine Receptor (1) Amyloid-β (2) Apoptosis (1) Autophagy (1) Carbonic Anhydrase (1) Cholinesterase (ChE) (5) Cytochrome P450 (1) Dopamine Transporter (2) Dopamine β-hydroxylase (1) Endogenous Metabolite (1) Histone Demethylase (1) HSV (1) iGluR (1) Isotope-Labeled Compounds (2) Tau Protein (1) α-synuclein (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (3) Infection (2) Neurological Disease (48)
Click Chemistry:	Alkynes (9)

Inhibitors & Agonists

Fluorescent Dye

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: Monoamine Oxidase Monoamine Transporter Xanthine Oxidase NADPH Oxidase Protoporphyrinogen IX oxidase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W001601

Budipine	iGluR	Neurological Disease
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .

HY-160002

MAO-B-IN-27	Monoamine Oxidase	Neurological Disease
MAO-B-IN-27 (Compound 12c) is a monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-27 has potent and selective MAO-B inhibitory effect for hMAO-B with an IC₅₀ values of 8.9 nM. MAO-B-IN-27 can be used for the research of parkinson's disease (PD) .

HY-147362

MAO-B-IN-14	Monoamine Oxidase	Neurological Disease
MAO-B-IN-14 (Compound 9) is a potent and selective monoamine oxidase-B (MAO-B) inhibitor with an IC₅₀ of 0.95 μM and a K_i of 0.55 μM against human MAO-B.

HY-117502

SL-25.1188	Monoamine Oxidase	Others
SL-25.1188 is a potent **monoamine oxidase B (MAO-B) inhibitor with K_i** values of 2.9 and 8.5 nM for human MAO-B and rat MAO-B, respectively. SL-25.1188 can be used for positron emission tomography .

HY-114915

PSB-1434

Monoamine Oxidase Neurological Disease

PSB-1434 is an inhibitor for monoamine oxidase B (MAO-B), with an IC₅₀ of 1.59 nM .

PSB-1434	Monoamine Oxidase	Neurological Disease
PSB-1434 is an inhibitor for monoamine oxidase B (MAO-B), with an IC₅₀ of 1.59 nM .

HY-146150

MAO-B-IN-12	Monoamine Oxidase	Neurological Disease
MAO-B-IN-12 (Compound 16c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.3 μM. MAO-B-IN-12 shows a neuroprotective activity .

HY-146149

MAO-B-IN-11	Monoamine Oxidase	Neurological Disease
MAO-B-IN-11 (Compound 8c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.3 μM. MAO-B-IN-11 shows a neuroprotective activity .

HY-151210

MAO-B-IN-17	Monoamine Oxidase	Neurological Disease
MAO-B-IN-17 is a selective monoamine oxidase B (MAO-B) inhibitor with the IC₅₀ value of 5.08 μM. MAO-B-IN-17 can be used in Parkinson’s disease research .

HY-151208

MAO-B-IN-16	Monoamine Oxidase	Neurological Disease
MAO-B-IN-16 is a selective monoamine oxidase B (MAO-B) inhibitor, with an IC₅₀ of 1.55 µM. MAO-B-IN-16 can be used in the study of central nervous disorders, such as parkinson's disease .

HY-143244

Monoamine Oxidase B inhibitor 1	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active and selective **monoamine oxidase B (MAO-B) inhibitor with an IC₅₀** of 0.02 nM. Monoamine Oxidase B inhibitor 1 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 1 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study .

HY-143245

Monoamine Oxidase B inhibitor 2	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active and selective **monoamine oxidase B (MAO-B) inhibitor with an IC₅₀** of 1.33 nM. Monoamine Oxidase B inhibitor 2 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 2 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study .

HY-144824

Monoamine oxidase/Aromatase-IN-1	Cytochrome P450 Monoamine Oxidase	Neurological Disease Cancer
Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a highly potent **monoamine oxidase (MAO) and aromatase dual inhibitor with IC₅₀*s of 39 nM and 31 nM for MAO-B* and aromatase, respectively. Monoamine oxidase/Aromatase-IN-1 can be used for researching neurological disorder and breast cancer .

HY-W792513

WAY-620147	Monoamine Oxidase	Neurological Disease
WAY-620147 (compound 6) is an N-(2-morpholinoethyl)nicotinamide derivative that inhibits monoamine oxidase (Monoamine Oxidase). WAY-620147 inhibits MAO-A and MAO-B with IC50s of 26 μM and 55 μM, respectively .

HY-N9540

Methyl citrate	Monoamine Oxidase	Neurological Disease
Methyl citrate is a Monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.23 mM). Methyl citrate is isolated from the fruits of Opuntia ficus-indica var. saboten Makino .

HY-163380

CA/MAO-B-IN-1	Carbonic Anhydrase	Neurological Disease
CA/MAO-B-IN-1 (Compound 78) is a dual inhibitor for human brain carbonic anhydrases (CA) and Monoamine Oxidase-B (MAO-B), with IC₅₀s of 8.8 and 7.0 nM, respectively. CA/MAO-B-IN-1 reveals a human oral absorption of 71.9% through in silico prediction .

HY-146347

MAO-B-IN-10	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated *MAO-B* (monoamine oxidase-B) inhibitor, with IC₅₀ of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research .

HY-116097

PSB-1491	Monoamine Oxidase	Neurological Disease
PSB-1491 is a selective and competitive **monoamine oxidase B (MAO-B) inhibitor with an IC₅₀** of 0.386 nM for hMAO-B. PSB-1491 shows >25000-fold selective versus MAO-A .

HY-161328

MAO-B-IN-31	Monoamine Oxidase α-synuclein Tau Protein	Neurological Disease
MAO-B-IN-31 (Compound 30) is an effective and selective inhibitor of monoamine oxidase B (monoamine oxidase B). The IC₅₀ value is 41 nM. MAO-B-IN-31 also inhibits α-syn and tau aggregation. MAO-B-IN-31 has neuroprotective activity .

HY-162061

ChEs/MAOs-IN-1	Monoamine Oxidase	Neurological Disease
ChEs/MAOs-IN-1 (Compound 4i) is a dual inhibitor of cholinesterases (ChEs) and monoamine oxidases (MAOs).ChEs/MAOs-IN-1 has IC₅₀ values of 0.048 μM, 0.89 μM, 3.58 μM, and 0.095 μM for AChE, BChE, *MAO-B* and *MAO-B* respectively. ChEs/MAOs-IN-1 can be used in the study of neurodegenerative diseases .

HY-U00015

MAO-IN-1

Monoamine Oxidase Neurological Disease

MAO-IN-1 is a monoamine oxidase B (MAO B) inhibitor with an IC₅₀ of 20 nM.

MAO-IN-1	Monoamine Oxidase	Neurological Disease
MAO-IN-1 is a monoamine oxidase B (MAO B) inhibitor with an IC₅₀ of 20 nM.

HY-162303

C175-0062	Monoamine Oxidase	Neurological Disease
C175-0062 is a monoamine oxidase B (MAO-B) inhibitor. C175-0062 can be used for the research of neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) .

HY-U00343

MAO-B-IN-1

Monoamine Oxidase Neurological Disease

MAO-B-IN-1 is an inhibitor of monoamine oxidase B, used for the research of neurological diseases.

MAO-B-IN-1	Monoamine Oxidase	Neurological Disease
MAO-B-IN-1 is an inhibitor of monoamine oxidase B, used for the research of neurological diseases.

HY-157934

MAO-IN-4	Monoamine Oxidase	Neurological Disease
MAO-IN-4 (Compound 2l) is a monoamine oxidase (MAO) inhibitor, with IC₅₀ values of 0.07 and 0.75 μM for MAO-A and MAO-B Enzymes, respectively. MAO-IN-4 can be used for the research of depression and Parkinson’s disease (PD) .

HY-157981

AChE-IN-60	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE-IN-60 (compound 6k) is a potant acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor with IC₅₀s of 27 nM and 43 nM, respectively. AChE-IN-60 also inhibits **monoamine oxidase (MAO)-A and MAO-B with IC₅₀**s of 353 nM and 716 nM, respectively .

HY-163322

MAO-A inhibitor 2	Monoamine Oxidase	Neurological Disease
MAO-A inhibitor 2 (compound HT4) is a **monoamine oxidase A (MAO-A) inhibitor with an IC₅₀** of 14.3 µM. MAO-A inhibitor 2 shows a less effect on MAO-B (IC₅₀ of 106 µM) and shows almost ineffective on xanthine oxidase (XO). MAO-A inhibitor 2 can be used for the neurodegenerative disorders and oxidative stress research .

HY-146314

MAO-B-IN-9	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent *MAO-B* (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-151094

FTEAA	Monoamine Oxidase	Neurological Disease
FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both **monoamine oxidase with IC₅₀*s of 0.52 μM (MAO-A),* 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research .

HY-B1558A

Bifemelane hydrochloride MCI-2016
Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of **monoamine oxidase A (MAO-A), with a K_i of 4.20 μM. Bifemelane hydrochloride also inhibits MAO-B noncompetitively with a K_i** of 46.0 μM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease .

HY-N7204

4-Hydroxyderricin 1 Publications Verification	Monoamine Oxidase Dopamine β-hydroxylase	Neurological Disease
4-Hydroxyderricin, the major active ingredients of Angelica keiskei Koidzumi, is a potent selective MAO-B (Monoamine oxidase inhibitors) inhibitor with an IC₅₀ of 3.43 μM. 4-Hydroxyderricin also mildly inhibits DBH (dopamine β-hydroxylase) activity. 4-Hydroxyderricin has antidepressant activity .

HY-D0004

Azure B Azure B chloride	Monoamine Oxidase	Neurological Disease
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of **monoamine oxidases (MAO)-A, with IC₅₀*s of 11 and 968 nM for recombinant human MAO-A and MAO-B*, respectively. Azure B possesses significant antidepressant-like effects .

HY-14201

Lazabemide Ro 19-6327	Monoamine Oxidase	Neurological Disease
Lazabemide (Ro 19-6327) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC₅₀=0.03 μM) but less active for MAO-A (IC₅₀>100 μM). Lazabemide inhibits monoamine uptake at high concentrations, the IC₅₀ values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease .

HY-14202

Lazabemide hydrochloride Ro 19-6327 hydrochloride	Monoamine Oxidase	Neurological Disease
Lazabemide hydrochloride (Ro 19-6327 hydrochloride) is a selective, reversible inhibitor of **monoamine oxidase B (MAO-B) (IC₅₀*=0.03 μM) but less active for MAO-A (IC₅₀>100 μM). Lazabemide inhibits monoamine* uptake at high concentrations, the IC₅₀ values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease .

HY-A0091

Pargyline hydrochloride 2 Publications Verification	Monoamine Oxidase	Cardiovascular Disease Cancer
Pargyline hydrochloride is an irreversible **monoamine oxidase (MAO) inhibitor with K_is of 13 μM and 0.5 μM for MAO-A and MAO-B**, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities . Pargyline (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-A0091A

Pargyline 2 Publications Verification	Monoamine Oxidase	Cardiovascular Disease Cancer
Pargyline is an irreversible **monoamine oxidase (MAO) inhibitor with K_is of 13 μM and 0.5 μM for MAO-A and MAO-B**, respectively. Pargyline has antihypertensive and anticancer activities . Pargyline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-103164

(E)-8-(3-Chlorostyryl)caffeine	Adenosine Receptor Monoamine Oxidase	Neurological Disease
(E)-8-(3-Chlorostyryl)caffeine is a selective adenosine A_2A receptor antagonist. (E)-8-(3-Chlorostyryl)caffeine inhibits **monoamine oxidase B (MAO-B) with a K_i** value of 70 nM by a pathway that is independent of its actions on the A_2A receptor. (E)-8-(3-Chlorostyryl)caffeine has the potential for Parkinson's disease research .

HY-N1638

1-Methyl-2-undecyl-4(1H)-quinolone	Monoamine Oxidase	Neurological Disease
1-Methyl-2-undecyl-4(1H)-quinolone is a potent, irreversible and selective inhibitor of type B monoamine oxidase (MAO-B). 1-Methyl-2-undecyl-4(1H)-quinolone shows a selective inhibition of *MAO-B* activity with the IC₅₀ and K_i values of 15.3 μM and 9.91 μM, respectively, but did not inhibit type A MAO (MAO-A) activity. Methyl-2-undecyl-4(1H)-quinolone, as a quinolone alkaloid, is isolated from fresh leaves and fruits of Evodia rutaecarpa HOOK. f. et THOMS .

HY-19333

OG-L002 1 Publications Verification	Histone Demethylase Monoamine Oxidase HSV	Infection
OG-L002 is a potent and highly selective LSD1 inhibitor with an IC₅₀ of 0.02 μM. OG-L002 is a potent **monoamine oxidases (MAO) inhibitor with IC₅₀*s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE* genes .

HY-N1636

1-Methyl-2-nonyl-4(1H)-quinolone	Monoamine Oxidase	Neurological Disease
1-Methyl-2-nonyl-4(1H)-quinolone, a quinolone alkaloid, is a potent and selective *MAO-B* (monoamine oxidase) inhibitor. 1-Methyl-2-nonyl-4(1H)-quinolone exhibites inhibitory activity on leukotriene biosynthesis, with an IC₅₀ of 12.1 μM .

HY-120419

PF9601N	Monoamine Oxidase	Neurological Disease
PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity . PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-101169

Tetrindole mesylate
Tetrindole mesylate is a selective inhibitor of monoamine oxidase A (MAO A). Tetrindole mesylate inhibits rat brain mitochondrial MAO A in a competitive manner with a K_i value of 0.4 μM and inhibits MAO B with a K_i of 110 μM. Tetrindole mesylate has antidepressant activity .

HY-70057

Safinamide 2 Publications Verification FCE 26743; EMD 1195686	Monoamine Oxidase	Neurological Disease
Safinamide is a potent, selective, and reversible **monoamine oxidase B (MAO-B) inhibitor (IC₅₀*=0.098 µM) over MAO-A (IC₅₀=580 µM) . Safinamide also blocks sodium channels* and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8 µM) than at resting (IC₅₀=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al .

HY-W008566

Norharmane Norharman; β-Carboline	Monoamine Oxidase Endogenous Metabolite	Infection Neurological Disease Cancer
Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible **monoamine oxidase inhibitor, with IC₅₀ values of 6.5 and 4.7 μM for MAO-A and MAO-B*, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana* seedlings .

HY-10399

Ladostigil TV-3326	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Ladostigil (TV-3326) is an orally active dual inhibitor of cholinesterase and brain-selective **monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE**, respectively. Ladostigil exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10399A

Ladostigil hydrochloride TV-3326 hydrochloride	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective **monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE**, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13779A

J147	Monoamine Oxidase Dopamine Transporter	Neurological Disease
J147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. J147 can pass the blood brain barrier (BBB). J147 can inhibit monoamine oxidase B (MAO B) and the dopamine transporter. J147 plays an impotant role in Alzheimer’s disease (AD) .

HY-151562

AChE/BuChE/MAO-B-IN-1	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BuChE/MAO-B-IN-1 (compound 19) is an inhibitor of human acetyl- (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B) with IC₅₀s of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. AChE/BuChE/MAO-B-IN-1 also exhibits high affinity to both the σ₁ and σ₂ receptors with K_i values of 42.8 nM (human σ₁ receptor) and 191 nM (rat σ₂ receptor), respectively. AChE/BuChE/MAO-B-IN-1 can be used for Alzheimer’s disease research .

HY-70057A

Safinamide mesylate 2 Publications Verification FCE 26743 mesylate; EMD 1195686 mesylate	Monoamine Oxidase	Cardiovascular Disease Neurological Disease
Safinamide (FCE 26743; EMD 1195686) mesylate is a potent, selective, and reversible **monoamine oxidase B (MAO-B) inhibitor (IC₅₀*=0.098 µM) over MAO-A (IC₅₀=580 nM) . Safinamide mesylate also blocks sodium channels* and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8 µM) than at resting (IC₅₀=262 µM) potentials. Safinamide mesylate has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke et.al .

HY-10400

Ladostigil hemitartrate TV-3326 hemitartrate	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective **monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE**, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease . Ladostigil (hemitartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-70057S1

Safinamide-d4-1 FCE 26743-d₄-1; EMD 1195686-d₄-1	Isotope-Labeled Compounds Monoamine Oxidase	Neurological Disease
Safinamide-d₄-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM)[1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].

HY-17447A

Tranylcypromine hydrochloride 4 Publications Verification SKF 385 hydrochloride
Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase *(MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO* A and MAO B with IC₅₀s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N9540

Methyl citrate	Cactaceae Ketones, Aldehydes, Acids Source classification Opuntia ficus-indica (L.) Mill. Plants	Monoamine Oxidase
Methyl citrate is a Monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.23 mM). Methyl citrate is isolated from the fruits of Opuntia ficus-indica var. saboten Makino .

HY-N7204

4-Hydroxyderricin 1 Publications Verification	Structural Classification Chalcones Monophenols Flavonoids Phenols Plants Umbelliferae Clerodendrum bungei Steud.	Monoamine Oxidase Dopamine β-hydroxylase
4-Hydroxyderricin, the major active ingredients of Angelica keiskei Koidzumi, is a potent selective MAO-B (Monoamine oxidase inhibitors) inhibitor with an IC₅₀ of 3.43 μM. 4-Hydroxyderricin also mildly inhibits DBH (dopamine β-hydroxylase) activity. 4-Hydroxyderricin has antidepressant activity .

HY-W008566

Norharmane Norharman; β-Carboline	Structural Classification Neurological Disease Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Biological Pesticide Research Indole Alkaloids Agricultural Research Infection Alkaloids Microorganisms Disease Research Fields Cancer	Monoamine Oxidase Endogenous Metabolite
Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible **monoamine oxidase inhibitor, with IC₅₀ values of 6.5 and 4.7 μM for MAO-A and MAO-B*, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana* seedlings .

HY-N1638

1-Methyl-2-undecyl-4(1H)-quinolone	Alkaloids Source classification Evodia rutaecarpa (Juss.) Benth. Rutaceae Quinoline Alkaloids Plants	Monoamine Oxidase
1-Methyl-2-undecyl-4(1H)-quinolone is a potent, irreversible and selective inhibitor of type B monoamine oxidase (MAO-B). 1-Methyl-2-undecyl-4(1H)-quinolone shows a selective inhibition of *MAO-B* activity with the IC₅₀ and K_i values of 15.3 μM and 9.91 μM, respectively, but did not inhibit type A MAO (MAO-A) activity. Methyl-2-undecyl-4(1H)-quinolone, as a quinolone alkaloid, is isolated from fresh leaves and fruits of Evodia rutaecarpa HOOK. f. et THOMS .

HY-N1636

1-Methyl-2-nonyl-4(1H)-quinolone	Alkaloids Classification of Application Fields Neurological Disease Source classification Rutaceae Quinoline Alkaloids Plants Disease Research Fields	Monoamine Oxidase
1-Methyl-2-nonyl-4(1H)-quinolone, a quinolone alkaloid, is a potent and selective *MAO-B* (monoamine oxidase) inhibitor. 1-Methyl-2-nonyl-4(1H)-quinolone exhibites inhibitory activity on leukotriene biosynthesis, with an IC₅₀ of 12.1 μM .

Cat. No.	Product Name	Chemical Structure

HY-14605S

Rasagiline-13C3 mesylate
Rasagiline- ¹³C₃ ((R)-AGN1135- ¹³C₃; TVP1012- ¹³C₃) mesylateis the deuterium labeledRasagiline (mesylate)(HY-14605) . Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43?nM and 412?nM for rat brain MAO B and A activity, respectively .

HY-70057S1

Safinamide-d4-1

Safinamide-d₄-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM)[1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride

(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

Cat. No.	Product Name		Classification